CRIS— CURIS INC

$0.50-0.50%

NasdaqMaterialsBiological Products, (No Diagnostic Substances)

1 insider bought $5K worth of CRIS in the last 30 days — 24.0x above historical baseline

Velocity Score — Last 19 Days

Velocity Score

23.98x

Current Rate (90d)

111.11 sh/day

Baseline Rate

—

Unique Insiders (90d)

Price Chart

Loading…

Insider Transactions

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-03-31	2026-04-01	KAITIN KENNETH I	Director	Purchase	10.0K	$0.55	$5K	11.4K	View ↗

No recent congressional transactions.

Revenue

No data

Operating Income

No data

Net Income

No data

Free Cash Flow

-$27.2M

+31.2% YoY

No annual data found.

Curis (CRIS) Q1 2026 Earnings Call Transcript

Curis, Inc. Q1 2026 Earnings Call Summary

Curis anticipates TakeAim CLL initial 5-patient dosing by mid-2026 while projecting cash runway into second half of '27

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript